1. Which of the following is a point on a clinical value compass for atopic dermatitis?

2. Which of the following is a cost that many prescribers and pharmacists fail to consider when working with patients who have AD?

3. A specialty pharmacist calls a patient with AD every two weeks and asks how often the patient has applied a PDE4 inhibitor and if she has moisturized at least twice daily. The pharmacist also tells the patient when her next refills are due and asks the patient if she will need the refill. The pharmacist documents the call in the electronic medical record. What is the pharmacist monitoring?

4. A specialty pharmacist calls a patient who has AD every month. The pharmacist reminds the patient that AD waxes and wanes, determines the severity of the patient's current symptoms, and reviews the eczema action plan to ensure the patient knows how to manage flares. The pharmacist asks about side effects (and reminds the patient of possible side effects) and asks if the patient will be able to refill the prescription when she needs it. The pharmacist documents the call in the electronic medical record. The health system analyzes collective data from the HER quarterly. What level of care is the pharmacist providing?

5. Which of the following is the BEST PAIR of items that can be used to measure (1) adherence and (2) outcomes in AD?

6. A very large specialty pharmacy conducts comprehensive assessment, education, and monitoring at the first patient contact, then follow up as frequently as necessary based on the patient's AD severity. Clinicians also manage side effects proactively and identify adherence barriers early. The pharmacy now has funding to take this program to the next level. What should they add to improve safety?

7. A health care system has decided to collect patient-reported outcomes from patients who have AD because this condition is so common. They wish to focus on comorbidities. Which of the following would be the best conditions to ask about?

8. A new and costly biologic enters the market. Clinical trials indicate that 93% of patients with AD achieve clear or almost clear skin within four months. You present this biologic to the formulary committee, but you have no real-world evidence to present. One of your colleagues suggests using a contract that ties the cost/reimbursement of this biologic to agreed-upon clinical circumstances, patient outcomes, or measures. What is she suggesting?

9. The organization for which you work has used the PO-SCORAD once quarterly in adult patients who have AD. They have used the results to address itching more aggressively, tailor treatment to individual patients, and improve adherence. Now, a pediatrician on staff wants to create a similar program for children, but he does not think the PO-SCORAD is appropriate. Which of the following would be the BEST PROM to use?

10. Which of the following statements describes an area where organizations and specialty pharmacies can improve data collection for new drugs or biologics?

« Return to Activity